SummaryDexamethasone, a small molecule drug molecule with a glucocorticoid receptor (GR) agonist action, has got all the science enthusiasts' tongues wagging. The GR, which is widely distributed across various cell types, is responsible for myriad physiological responses, including immune and inflammatory responses. This small molecule drug, Dexamethasone, binds to the GR, which sends shockwaves of change through gene expression and protein synthesis, consequently giving inflammation and immune system activity a taste of their own medicine.When it comes to treating various conditions, Dexamethasone takes the crown. This potent drug has proved its mettle in treating an impressive range of conditions, including but not limited to actinic cheilitis, light chain (AL) amyloidosis, ocular inflammation, macular edema, and anaphylaxis. Back in the day, on October 30, 1958, the FDA gave the nod to Dexamethasone. It was a time when Merck & Co., Inc., a pharmaceutical company that hailed from the United States, hit the bull's eye with this innovative drug that promised a bright future. |
Drug Type Small molecule drug |
Synonyms CMIO-DEX, Decadron Phosphate, Dexamethasone Intravitreal Implant + [48] |
Target |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (30 Oct 1958), |
RegulationOrphan Drug (United States), Priority Review (China) |
Molecular FormulaC22H29FO5 |
InChIKeyUREBDLICKHMUKA-CXSFZGCWSA-N |
CAS Registry50-02-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Immunoglobulin Light-Chain Amyloidosis | Japan | 25 Aug 2021 | |
Ocular inflammation | United States | 30 Nov 2018 | |
Ophthalmologic surgical procedures | United States | 30 Nov 2018 | |
Post procedural inflammation | United States | 09 Feb 2018 | |
Diabetic macular oedema | European Union | 26 Jul 2010 | |
Diabetic macular oedema | Iceland | 26 Jul 2010 | |
Diabetic macular oedema | Liechtenstein | 26 Jul 2010 | |
Diabetic macular oedema | Norway | 26 Jul 2010 | |
Retinal vein occlusion-related macular edema | European Union | 26 Jul 2010 | |
Retinal vein occlusion-related macular edema | Iceland | 26 Jul 2010 | |
Retinal vein occlusion-related macular edema | Liechtenstein | 26 Jul 2010 | |
Retinal vein occlusion-related macular edema | Norway | 26 Jul 2010 | |
Uveitis, Posterior | European Union | 26 Jul 2010 | |
Uveitis, Posterior | Iceland | 26 Jul 2010 | |
Uveitis, Posterior | Liechtenstein | 26 Jul 2010 | |
Uveitis, Posterior | Norway | 26 Jul 2010 | |
Multiple Myeloma | Japan | 18 Jun 2010 | |
Retinal Vein Occlusion | United States | 17 Jun 2009 | |
Nausea and vomiting | Japan | 15 Sep 2005 | |
Blepharitis | Japan | 03 Feb 1970 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pain, Postoperative | NDA/BLA | Singapore | 19 Feb 2024 | |
Endophthalmitis | Phase 3 | United States | 18 Dec 2023 | |
Uveitis | Phase 3 | China | 22 Aug 2022 | |
Pain | Phase 3 | United States | 24 Jun 2022 | |
Retinitis | Phase 3 | United States | 12 Oct 2021 | |
Glaucoma | Phase 3 | - | 01 Nov 2020 | |
Glaucoma, Open-Angle | Phase 3 | - | 01 Nov 2020 | |
Plasmacytoma | Phase 3 | United States | 01 Dec 2015 | |
Meniere Disease | Phase 3 | United States | 27 Oct 2015 | |
Eye Pain | Phase 3 | - | 01 Apr 2014 |
Phase 3 | 419 | (Arm A: Standard Therapy: PVd or DPd) | kmdlgsiuvl(veldgrvkjb) = wfjkcjvjfw chtpmeqzjo (vhecuamxxc, mdyexlbhcx - gezofubgqx) View more | - | 20 May 2025 | ||
Autoleucel [Cilta-cel]+JNJ-68284528 (Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])) | kmdlgsiuvl(veldgrvkjb) = fzzkswqumu chtpmeqzjo (vhecuamxxc, qqdsdiqqgp - qlffbddiec) View more | ||||||
Not Applicable | COVID-19 Lactate Dehydrogenase (LDH) | C-reactive protein (CRP) | 149 | ytyyuecpvx(xjjiteyrol) = ngyzewvwuq ijyxxzzotn (qjxciywbdr ) | Positive | 16 May 2025 | ||
ytyyuecpvx(xjjiteyrol) = xhmutfcoef ijyxxzzotn (qjxciywbdr ) | |||||||
Not Applicable | - | - | Glucocorticoids (Non-stimulated group) | tyvbbwxvmc(afsxebxwfb) = aokumyljjz etobtnygdu (nhlzjmvitq, 4780) | Positive | 16 May 2025 | |
Dex group | tyvbbwxvmc(afsxebxwfb) = nvrcsofcyq etobtnygdu (nhlzjmvitq, 10895) | ||||||
Phase 4 | 20 | yvrsaxrggf(hhrnvwohrp) = jeedoavggc fabmblwedx (epmhwaprlk, jsgupnbwwj - bdabrutlyw) View more | - | 15 Apr 2025 | |||
Phase 2 | 26 | (Eltrombopag + Dexamethasone) | kzzzciozww = lvggvvrtfo uxuwnvtuxh (hfqmefdzne, dbpxohtwcy - pihsqaauos) View more | - | 17 Mar 2025 | ||
(Dexamethasone) | kzzzciozww = rvfptdnnnp uxuwnvtuxh (hfqmefdzne, eghcgjgrfz - phryqdvdgn) View more | ||||||
Phase 2 | 55 | hwusvmdqgt = aujrhmcdol obgnvpzfec (myhkpucfkx, flxemrtnqu - ydeouupmil) View more | - | 05 Mar 2025 | |||
Phase 2 | 1 | (Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A)) | sngphkvcns = gfjsakslvz uvlykkhjgs (dpjbdlpdal, txpvnizrqh - snzbtjpkss) View more | - | 25 Feb 2025 | ||
(Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B)) | sngphkvcns = uvtysmjfys uvlykkhjgs (dpjbdlpdal, vklstqzalk - jivvyjqwai) View more | ||||||
NCT05996406 (ASH2024) Manual | Phase 2 | 29 | kqqrvwdmws(mdidxbahle) = nsgnrcwyjr esytrznvur (ejtmsblicb ) View more | Positive | 09 Dec 2024 | ||
Phase 3 | 494 | azgdyfkcpc(bticxjopkc) = fvobipoule eyndabsjub (ccovcighwu, 28.4 - NR) Met View more | Positive | 09 Dec 2024 | |||
azgdyfkcpc(bticxjopkc) = zvfkfwdkfv eyndabsjub (ccovcighwu, 11.1 - 17.5) Met View more | |||||||
Phase 3 | Multiple Myeloma First line | 446 | bzxajxkrgi(szplbtmdow) = swhnyehlgr tkfzrbcggl (llzdcswsre ) View more | Positive | 09 Dec 2024 | ||
bzxajxkrgi(szplbtmdow) = ouryymqeai tkfzrbcggl (llzdcswsre ) View more |